What Element Science does

Element Science, Inc. is a San Francisco-based medical device and digital health company founded in 2011 that develops the Jewel Patch Wearable Cardioverter Defibrillator (P-WCD), a clinically validated, patch-based wearable designed for patients at temporary elevated risk of sudden cardiac arrest. The device continuously monitors cardiac rhythms using ECG sensors and on-body electrodes, applies proprietary machine learning algorithms to detect and classify life-threatening arrhythmias such as ventricular tachycardia and ventricular fibrillation, and automatically delivers therapeutic defibrillation shocks. Its core technical differentiator versus legacy wearable cardioverter defibrillators is a miniaturized, water-resistant, under-clothing patch form factor intended to materially improve patient compliance, paired with a connected care digital platform (clinical.elementscience.com) and the Jewel companion App for physician remote monitoring and patient engagement.

The company derives revenue from the sale of the prescribed Jewel Patch WCD through healthcare provider and health system channels, with the product currently commercially available in limited U.S. markets and additional distribution enabled by CE Mark and UKCA Mark approval in Europe and the United Kingdom. Sales are directed by cardiologists and electrophysiologists to a defined clinical use case (post-MI, post-cardiac procedure, or bridge to permanent ICD implantation), and the company states an intent to reach over 500,000 patients in the U.S. and Europe. The business is venture capital-backed, with over $145 million raised to date from Third Rock Ventures, Google Ventures, Deerfield Management, Qiming, Cormorant, and Invus, and the company is operating under a new CEO and an expanded commercial leadership team installed in 2024-2026 to drive U.S. and European scale-up following FDA Premarket Approval in May 2025.

Name

Element Science

Legal name

Element Science, Inc.

Website

https://elementscience.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

51–100 employees

Short description

Element Science is a San Francisco-based medical device company that develops the Jewel Patch, an FDA-approved, ML-enabled wearable cardioverter defibrillator for patients at temporary elevated risk of sudden cardiac arrest, sold via clinical channels in the U.S. and Europe.

Ownership category

akta.pro rank

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Medical Equipment and Supplies Manufacturing (3391)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cardiac Rhythm Management (Pacemakers, ICDs, CRT) (HLAHAFAC)

akta.pro secondary industries

Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)

Keywords

• Wearable defibrillator devices
• Cardiac rhythm management
• Sudden cardiac arrest protection
• Continuous cardiac monitoring
• Medical device digital health

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Jewel Patch WCD Device Sales: Element Science generates revenue through the sale of its Jewel Patch Wearable Cardioverter Defibrillator. The device is a prescribed medical device for patients at temporary elevated risk of sudden cardiac arrest. Revenue is likely derived from healthcare provider/health system procurement and potentially recurring revenue from consumables/patch replacements during the wear period.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Element Science develops and sells the Jewel Patch Wearable Cardioverter Defibrillator (P-WCD), a prescription medical device that continuously monitors heart rhythms and automatically delivers therapeutic shocks to treat life-threatening arrhythmias in patients at temporary elevated risk of sudden cardiac arrest. The device is complemented by the Jewel App companion mobile application and a connected digital platform that enables remote patient monitoring for cardiology providers.

Product overview

Element Science offers the Jewel® Patch Wearable Cardioverter Defibrillator (P-WCD) as its primary product—a groundbreaking patch-based wearable defibrillator that provides continuous cardiac monitoring and automatic treatment of life-threatening arrhythmias. The product is complemented by the Jewel® App, a companion mobile application that provides patient notifications and device management capabilities. The company is developing a next-generation wearable digital platform combining human-centric engineering, sophisticated machine learning, and rigorous medical device standards. The Jewel Patch is currently commercially available in limited U.S. markets and has received regulatory approvals including FDA Premarket Approval (May 2025), CE Mark (January 2024), and UKCA Mark (January 2024).

Differentiator

Problem solved

Functional benefit

Brands

• Jewel Patch Wearable Cardioverter Defibrillator (P-WCD): The company's flagship product - a patch-based wearable cardioverter defibrillator designed for patients at risk of sudden cardiac arrest.

Quantifiable outcome

• 436,000 Americans die from sudden cardiac arrest every year; 350,000+ cardiac arrests occur outside the hospital annually
• +3 more outcomes

Named customers1 record

Segments1 record

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Baylor Scott and White Research InstitutecoreStrategic or Co-development PartnerJaved Butler, MD, President of Baylor Scott and White Research Institute, serves as a Principal Investigator for the Jewel IDE Study. This clinical partnership validates the device through rigorous clinical investigation and generates peer-reviewed evidence for regulatory submissions and physician adoption.
• The Ohio State University Wexner Medical CentercoreStrategic or Co-development PartnerJohn Hummel, MD, Director of Electrophysiology at The Ohio State University, served as a Principal Investigator for the Jewel IDE pivotal study. The academic medical center partnership generates clinical evidence for the device through rigorous study execution.
• Mount Sinai Health SystemcoreStrategic or Co-development PartnerRoxana Mehran, MD, Director of Interventional Cardiovascular Research at Mount Sinai, served as a Principal Investigator for the Jewel IDE Study. This partnership provides high-profile academic clinical validation and contributes to peer-reviewed publications supporting the device.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• ZOLL Medical (LifeVest): ZOLL Medical, an Asahi Kasei company, manufactures the LifeVest, the dominant wearable cardioverter defibrillator on the market. Direct competitor to Element Science's Jewel Patch WCD in the same physician-prescribed WCD category for patients at temporary sudden cardiac arrest risk.
• Defibtech: Defibtech manufactures AEDs and related defibrillator products for professional and lay responder use. Smaller direct competitor in the broader defibrillator device category, with overlapping clinical and emergency response use cases but a different product format (AED vs. prescribed wearable).

Emerging players

• Kestra Medical Technologies: Kestra Medical is developing next-generation wearable cardiac defibrillation and rhythm management solutions. Comparable emerging competitor in the WCD and wearable cardiac therapeutic space, also pursuing regulatory approvals and commercial launch against the established LifeVest franchise.
• iRhythm Technologies: iRhythm Technologies (NASD: IRTC) is a digital cardiac monitoring company founded by Element Science's founder Uday Kumar. While focused on diagnostic ECG monitoring (Zio patch) rather than therapeutic defibrillation, it shares the same founder DNA, clinical customer base, and patch-based wearable cardiac device category.
• Cardiac Insight: Cardiac Insight is a privately held developer of wearable cardiac sensors and ECG-based diagnostic technologies. Emerging player in the wearable cardiac monitoring space, with comparable form factor ambitions and AI-driven arrhythmia detection capabilities.
• HeartBeam: HeartBeam is a small-cap public company developing portable ECG and cardiac monitoring technology for at-home detection of heart attacks and arrhythmias. Emerging player in connected cardiac diagnostics with similar wearable + AI detection approach, though focused on diagnostic rather than therapeutic indication.

Broad incumbents

• Medtronic: Medtronic is a global leader in implantable cardiac rhythm management devices (ICDs, CRT-Ds) and broader cardiovascular care. As a broad incumbent in the cardiac rhythm management space, it represents the destination for patients who ultimately need an implantable device after the WCD bridge period.
• Boston Scientific: Boston Scientific is a major manufacturer of ICDs and cardiac rhythm management devices, among other cardiovascular therapies. Broad incumbent in the same clinical workflow that ends with permanent ICD implantation, and a potential strategic acquirer given the WCD market adjacency.
• Abbott: Abbott manufactures implantable cardioverter defibrillators and broader cardiac rhythm management solutions, including the recently acquired CardiacSense wearable cardiac monitoring portfolio. Broad incumbent with potentially adjacent offerings in wearable cardiac monitoring and eventual therapeutic devices.
• Philips (HeartStart): Philips HeartStart is a leading brand of automated external defibrillators (AEDs) and broader cardiac emergency response solutions. Broad incumbent in the defibrillation therapy space, with overlapping clinical customers and a different deployment model (AED vs. prescribed wearable).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/element-science-inc-

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Element Science